NY Archives - Page 3 of 4 - 2021 CMSC Annual Meeting

October 25, 2021

Does Frequency and Severity of COVID-19 Differ By Disease Modifying Therapy in MS Patients?

Background: Some authors have reported positive associations between B-cell-depleting (anti-CD20) therapies and COVID-19 infection risk or...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Is There Wearing Off with Ocrelizumab? Preliminary Results of Symptom Burden on Ocrelizumab, a Longitudinal Study (SymBOLS).

Background: Ocrelizumab (OCR), a humanized, anti-CD20 antibody therapy approved for multiple sclerosis (MS), is given at 6-month intervals....

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Expand Study

Background: Siponimod is a selective S1P receptor (S1P1 and S1P5) modulator, approved in the USA for treatment of relapsing forms of MS,...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Characteristics and Outcomes By Employment and Education Status for Patients Treated with Peginterferon Beta-1a or Intramuscular Interferon Beta-1a

Background: Although socioeconomic disparities that lead to differences in multiple sclerosis (MS) outcomes have been identified, specific...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Treatment Persistence, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World: Design of the Phase 4 ExperienceUS Study

Background: Diroximel fumarate (DRF) is an oral fumarate approved in the United States (US) for relapsing multiple sclerosis (MS). DRF...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Multiple Sclerosis Patients Initiating Ofatumumab in the Real-World: Early 3 Months Data

Background: The efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. This analysis provides the first account...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data

Background: The majority of real-world data (RWD) on disease-modifying treatments (DMTs) for multiple sclerosis (MS) is based on clinical...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab

Background: A global pandemic of COVID-19 has resulted in over 78 million cases as of 23 December 2020. Risks of COVID-19 in people with...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years

Background: In the EXPAND Core study, siponimod significantly reduced the risk of 3-/6-months(m) confirmed disability progression...

Read More →

Platform-Disease Modifying Therapies

October 25, 2021

Improvements in Work Productivity and Activity Impairment in Ocrelizumab-Treated Patients with RRMS: 2-Year Data from the CASTING Study

Background: The Work Productivity and Activity Impairment (WPAI) questionnaire is a patient-reported outcome that assesses percentage of...

Read More →

2021 CMSC Annual Meeting

Tag: NY

Does Frequency and Severity of COVID-19 Differ By Disease Modifying Therapy in MS Patients?

Is There Wearing Off with Ocrelizumab? Preliminary Results of Symptom Burden on Ocrelizumab, a Longitudinal Study (SymBOLS).

Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Expand Study

Characteristics and Outcomes By Employment and Education Status for Patients Treated with Peginterferon Beta-1a or Intramuscular Interferon Beta-1a

Treatment Persistence, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World: Design of the Phase 4 ExperienceUS Study

Multiple Sclerosis Patients Initiating Ofatumumab in the Real-World: Early 3 Months Data

Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data

Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab

Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years

Improvements in Work Productivity and Activity Impairment in Ocrelizumab-Treated Patients with RRMS: 2-Year Data from the CASTING Study

MAILING ADDRESS

CONTACT US

FOLLOW US